Skip to content

Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study

Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07289711
Acronym
VATIC
Enrollment
500
Registered
2025-12-17
Start date
2025-12-29
Completion date
2026-12-31
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Brief summary

Acute respiratory distress syndrome (ARDS) is a common and life-threatening condition in intensive care units, characterized by substantial biological and clinical heterogeneity. Differences in patients' inflammatory responses, baseline immune function, and organ failure patterns contribute to variability in ARDS severity, treatment response, and clinical outcomes. Precision classification of ARDS based on biological and inflammatory characteristics may therefore be essential for improving patient outcomes. Previous analyses of randomized clinical trials have identified two reproducible inflammatory subphenotypes-"hyperinflammatory" and "hypoinflammatory"-which differ in organ dysfunction profiles, clinical trajectories, and responses to treatments such as fluid management strategies, corticosteroids, and ventilatory interventions. However, key uncertainties remain, including whether these inflammatory subphenotypes can be validated in Chinese ARDS populations, how various bedside prediction models perform in identifying these subphenotypes, and whether model-based subphenotype identification can guide individualized treatment decisions. This multicenter cohort study aims to: (1) validate inflammatory subphenotypes of ARDS using latent class analysis; (2) compare the predictive performance of existing bedside models for subphenotype identification; and (3) assess whether subphenotype assignment based on prediction models can guide individualized treatment strategies, including fluid management, PEEP titration, and corticosteroid use. In addition to these primary aims, the study may include other exploratory objectives, such as evaluating subphenotype stability over time, characterizing biological pathways associated with subphenotypes, and assessing additional treatment-response patterns to support future precision ARDS management strategies.

Interventions

OTHERARDS Inflammatory Subphenotypes

ARDS patients with idfferent Inflammatory Subphenotypes

Sponsors

Southeast University, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years. 2. ARDS with new Global definition. 3. Onset of ARDS within 72 hours.

Exclusion criteria

1. Refusal of informed consent by the patient's legally authorized representative. 2. Patients expected to die within 24 hours 3. Receiving extracorporeal membrane oxygenation at the time of recruitment

Design outcomes

Primary

MeasureTime frameDescription
28-day mortalityFrom inclusion to 28 daysThe proportion of patients who are died within 28 days

Secondary

MeasureTime frameDescription
60-day mortalityFrom inclusion to 60 daysThe proportion of patients who are died within 60 days
Ventilator-free days at 28 daysFrom inclusion to 28 daysDays alive without endotracheal intubation and invasive mechanical ventilation
Vasopressor-free days at 28 daysFrom inclusion to 28 daysDays alive without use of vasopressor

Countries

China

Contacts

CONTACTHui Chen, MD
huichen.icu@gmail.com+8618006138640

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026